Angiotensin receptor antagonists to prevent sudden death in heart failure: does the dose matter?

Abstract

International guidelines recommend ICD implantation in patients with severe left ventricular dysfunction of any origin only after careful optimization of medical therapy. Indeed, major randomized clinical trials suggest that suboptimal use of fundamental drugs, such as ACE inhibitors (ACE-i) and beta-blockers, may affect ICD shock-free survival, sudden cardiac death (SCD), and overall mortality. While solid evidence in favour of pharmacological therapy based on ACE-i with or without beta-blockers is available, data on SCD in HF patients treated with angiotensin receptor blockers (ARBs) are limited. The present paper systematically analyses the impact of ARBs on SCD in HF and reviews the contributory role of the renin-angiotensin system (RAS) to the establishment of arrhythmic substrates. The following hypothesis is supported: (1) the RAS is a critical component of the electrical remodelling of the failing myocardium, (2) RAS blockade reduces the risk of SCD, and (3) ARBs represent a powerful tool to improve overall survival and possibly reduce the risk of SCD provided that high doses are employed to achieve optimal AT1-receptor blockade.

• Authors: Pietro Francia, Francesca Palano, Giuliano Tocci, Carmen Adduci, Agnese Ricotta, Lorenzo Semprini, Massimo Caprinozzi, Cristina Balla, Massimo Volpe
• Journal: ISRN cardiology (ISRN Cardiol) Vol. 2014 Pg. 652421 ( 2014) ISSN: 2090-5580 [Print] Egypt
• PMID: 24653841 (Publication Type: Journal Article, Review)